{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:41:33Z","timestamp":1785544893533,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100020207","name":"Health Commission of Sichuan Province","doi-asserted-by":"publisher","award":["ChuanGanYan 2022-119"],"award-info":[{"award-number":["ChuanGanYan 2022-119"]}],"id":[{"id":"10.13039\/501100020207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11096-024-01757-3","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T12:02:02Z","timestamp":1718884922000},"page":"1307-1316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Liver injury associated with endothelin receptor antagonists: a pharmacovigilance study based on FDA adverse event reporting system data"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3813-0701","authenticated-orcid":false,"given":"Jinjian","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5313-5193","authenticated-orcid":false,"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"issue":"1","key":"1757_CR1","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","volume":"53","author":"G Simonneau","year":"2019","unstructured":"Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. https:\/\/doi.org\/10.1183\/13993003.01913-2018.","journal-title":"Eur Respir J"},{"issue":"5","key":"1757_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","volume":"115","author":"GE D'Alonzo","year":"1991","unstructured":"D\u2019Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343\u20139. https:\/\/doi.org\/10.7326\/0003-4819-115-5-343.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1757_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","volume":"186","author":"E Stacher","year":"2012","unstructured":"Stacher E, Graham BB, Hunt JM, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186(3):261\u201372. https:\/\/doi.org\/10.1164\/rccm.201201-0164OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1757_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00441-016-2539-y","volume":"367","author":"RM Tuder","year":"2017","unstructured":"Tuder RM. Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res. 2017;367(3):643\u20139. https:\/\/doi.org\/10.1007\/s00441-016-2539-y.","journal-title":"Cell Tissue Res"},{"issue":"25","key":"1757_CR5","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMra2000348","volume":"385","author":"PM Hassoun","year":"2021","unstructured":"Hassoun PM. Pulmonary arterial hypertension. N Engl J Med. 2021;385(25):2361\u201376. https:\/\/doi.org\/10.1056\/NEJMra2000348.","journal-title":"N Engl J Med"},{"issue":"2","key":"1757_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.chest.2016.03.031","volume":"150","author":"H-L Liu","year":"2016","unstructured":"Liu H-L, Chen X-Y, Li J-R, et al. Efficacy and safety of pulmonary arterial hypertension-specific therapy in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials. Chest. 2016;150(2):353\u201366. https:\/\/doi.org\/10.1016\/j.chest.2016.03.031.","journal-title":"Chest"},{"issue":"23","key":"1757_CR7","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.742510.","journal-title":"Circulation"},{"issue":"12","key":"1757_CR8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896\u2013903. https:\/\/doi.org\/10.1056\/NEJMoa012212.","journal-title":"N Engl J Med"},{"issue":"9","key":"1757_CR9","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1213917.","journal-title":"N Engl J Med"},{"issue":"2","key":"1757_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/bcpt.13033","volume":"123","author":"M Bedan","year":"2018","unstructured":"Bedan M, Grimm D, Wehland M, et al. A focus on macitentan in the treatment of pulmonary arterial hypertension. Basic Clin Pharmacol Toxicol. 2018;123(2):103\u201313. https:\/\/doi.org\/10.1111\/bcpt.13033.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"1757_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1183\/09031936.00094409","volume":"34","author":"MM Hoeper","year":"2009","unstructured":"Hoeper MM. Liver toxicity: the Achilles\u2019 heel of endothelin receptor antagonist therapy? Eur Respir J. 2009;34(3):529\u201330. https:\/\/doi.org\/10.1183\/09031936.00094409.","journal-title":"Eur Respir J"},{"issue":"9630","key":"1757_CR12","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","volume":"371","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093\u2013100. https:\/\/doi.org\/10.1016\/S0140-6736(08)60919-8.","journal-title":"Lancet"},{"issue":"2","key":"1757_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijcard.2013.12.179","volume":"172","author":"G Simonneau","year":"2014","unstructured":"Simonneau G, Gali\u00e8 N, Jansa P, et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol. 2014;172(2):332\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2013.12.179.","journal-title":"Int J Cardiol"},{"issue":"11","key":"1757_CR14","doi-asserted-by":"publisher","first-page":"e003896","DOI":"10.1161\/JAHA.116.003896","volume":"5","author":"A Wei","year":"2016","unstructured":"Wei A, Gu Z, Li J, et al. Clinical adverse effects of endothelin receptor antagonists:insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials. J Am Heart Assoc. 2016;5(11):e003896. https:\/\/doi.org\/10.1161\/JAHA.116.003896.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"1757_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.21037\/cdt.2019.03.02","volume":"9","author":"Y-J Zhang","year":"2019","unstructured":"Zhang Y-J, Wang N, Gu Z-C, et al. A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension. Cardiovasc Diagn Ther. 2019;9(3):239\u201349. https:\/\/doi.org\/10.21037\/cdt.2019.03.02.","journal-title":"Cardiovasc Diagn Ther."},{"issue":"1","key":"1757_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.healun.2006.10.019","volume":"26","author":"RL Benza","year":"2007","unstructured":"Benza RL, Mehta S, Keogh A, et al. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant. 2007;26(1):63\u20139. https:\/\/doi.org\/10.1016\/j.healun.2006.10.019.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"1757_CR17","doi-asserted-by":"publisher","first-page":"e12150","DOI":"10.1002\/pul2.12150","volume":"12","author":"VV McLaughlin","year":"2022","unstructured":"McLaughlin VV, Channick R, Kim NH, et al. Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit\u00ae USers Registry (OPUS) and OPsumit\u00ae Historical USers cohort (OrPHeUS). Pulm Circ. 2022;12(4):e12150. https:\/\/doi.org\/10.1002\/pul2.12150.","journal-title":"Pulm Circ"},{"issue":"1","key":"1757_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jacc.2012.03.025","volume":"60","author":"O Ben-Yehuda","year":"2012","unstructured":"Ben-Yehuda O, Pizzuti D, Brown A, et al. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2012;60(1):80\u20131. https:\/\/doi.org\/10.1016\/j.jacc.2012.03.025.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1757_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jamia\/ocv063","volume":"23","author":"HJ Duggirala","year":"2016","unstructured":"Duggirala HJ, Tonning JM, Smith E, et al. Use of data mining at the food and drug administration. J Am Med Inform Assoc. 2016;23(2):428\u201334. https:\/\/doi.org\/10.1093\/jamia\/ocv063.","journal-title":"J Am Med Inform Assoc"},{"key":"1757_CR20","doi-asserted-by":"publisher","first-page":"692828","DOI":"10.3389\/fphar.2022.692828","volume":"13","author":"B Wu","year":"2022","unstructured":"Wu B, Luo M, Wu F, et al. Acute kidney injury associated with remdesivir: a comprehensive pharmacovigilance analysis of Covid-19 reports in FAERS. Front Pharmacol. 2022;13:692828. https:\/\/doi.org\/10.3389\/fphar.2022.692828.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1757_CR21","doi-asserted-by":"publisher","first-page":"10709","DOI":"10.1038\/s41598-021-90108-7","volume":"11","author":"B Wu","year":"2021","unstructured":"Wu B, Hu Q, Tian F, et al. A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data. Sci Rep. 2021;11(1):10709. https:\/\/doi.org\/10.1038\/s41598-021-90108-7.","journal-title":"Sci Rep"},{"issue":"2","key":"1757_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.yrtph.2014.09.007","volume":"70","author":"CM Hunt","year":"2014","unstructured":"Hunt CM, Yuen NA, Stirnadel-Farrant HA, et al. Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database. Regul Toxicol Pharmacol. 2014;70(2):519\u201326. https:\/\/doi.org\/10.1016\/j.yrtph.2014.09.007.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"3","key":"1757_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.yrtph.2015.05.004","volume":"72","author":"A Suzuki","year":"2015","unstructured":"Suzuki A, Yuen NA, Ilic K, et al. Comedications alter drug-induced liver injury reporting frequency: dat a mining in the WHO VigiBase\u2122. Regul Toxicol Pharmacol. 2015;72(3):481\u201390. https:\/\/doi.org\/10.1016\/j.yrtph.2015.05.004.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"1757_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321. https:\/\/doi.org\/10.1007\/s002280050466.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1757_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Van Puijenbroek","year":"2002","unstructured":"Van Puijenbroek EP, Bate A, Leufkens HGM, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1757_CR26","doi-asserted-by":"publisher","first-page":"204589402110543","DOI":"10.1177\/20458940211054304","volume":"11","author":"NP Nickel","year":"2021","unstructured":"Nickel NP, Galura GM, Zuckerman MJ, et al. Liver abnormalities in pulmonary arterial hypertension. Pulm Circ. 2021;11(4):20458940211054304. https:\/\/doi.org\/10.1177\/20458940211054304.","journal-title":"Pulm Circ"},{"issue":"162","key":"1757_CR27","doi-asserted-by":"publisher","first-page":"200330","DOI":"10.1183\/16000617.0330-2020","volume":"30","author":"C Cheron","year":"2021","unstructured":"Cheron C, McBride SA, Antigny F, et al. Sex and gender in pulmonary arterial hypertension. Eur Respir Rev. 2021;30(162):200330. https:\/\/doi.org\/10.1183\/16000617.0330-2020.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"1757_CR28","doi-asserted-by":"publisher","first-page":"e87548","DOI":"10.1371\/journal.pone.0087548","volume":"9","author":"E-I Lepist","year":"2014","unstructured":"Lepist E-I, Gillies H, Smith W, et al. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes. PLoS ONE. 2014;9(1):e87548. https:\/\/doi.org\/10.1371\/journal.pone.0087548.","journal-title":"PLoS ONE"},{"issue":"4","key":"1757_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1067\/mcp.2001.114667","volume":"69","author":"K Fattinger","year":"2001","unstructured":"Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001;69(4):223\u201331. https:\/\/doi.org\/10.1067\/mcp.2001.114667.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1757_CR30","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.jaip.2019.05.034","volume":"7","author":"DA Khan","year":"2019","unstructured":"Khan DA, Knowles SR, Shear NH. Sulfonamide hypersensitivity: fact and fiction. J Allergy Clin Immunol Pract. 2019;7(7):2116\u201323. https:\/\/doi.org\/10.1016\/j.jaip.2019.05.034.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"1757_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1183\/09031936.00078207","volume":"31","author":"J Dupuis","year":"2008","unstructured":"Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J. 2008;31(2):407\u201315. https:\/\/doi.org\/10.1183\/09031936.00078207.","journal-title":"Eur Respir J"},{"issue":"13\u201314","key":"1757_CR32","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.lfs.2012.02.003","volume":"91","author":"L Ling","year":"2012","unstructured":"Ling L, Kuc RE, Maguire JJ, et al. Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice. Life Sci. 2012;91(13\u201314):716\u201322. https:\/\/doi.org\/10.1016\/j.lfs.2012.02.003.","journal-title":"Life Sci"},{"issue":"1","key":"1757_CR33","doi-asserted-by":"publisher","first-page":"19772","DOI":"10.1038\/s41598-022-21816-x","volume":"12","author":"G Xu","year":"2022","unstructured":"Xu G, Gong Y, Lu F, et al. Endothelin receptor B enhances liver injury and pro-inflammatory responses by increasing G-protein-coupled receptor kinase-2 expression in primary biliary cholangitis. Sci Rep. 2022;12(1):19772. https:\/\/doi.org\/10.1038\/s41598-022-21816-x.","journal-title":"Sci Rep"},{"issue":"6","key":"1757_CR34","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/hep.20244","volume":"39","author":"Y Ling","year":"2004","unstructured":"Ling Y, Zhang J, Luo B, et al. The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat. Hepatology. 2004;39(6):1593\u2013602. https:\/\/doi.org\/10.1002\/hep.20244.","journal-title":"Hepatology"},{"issue":"6","key":"1757_CR35","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.chest.2022.06.042","volume":"162","author":"S Wu","year":"2022","unstructured":"Wu S, Hoang HB, Yang JZ, et al. Drug-drug interactions in the management of patients with pulmonary arterial hypertension. Chest. 2022;162(6):1360\u201372. https:\/\/doi.org\/10.1016\/j.chest.2022.06.042.","journal-title":"Chest"},{"issue":"8","key":"1757_CR36","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1124\/dmd.106.013615","volume":"35","author":"A Treiber","year":"2007","unstructured":"Treiber A, Schneiter R, H\u00e4usler S, et al. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007;35(8):1400\u20137. https:\/\/doi.org\/10.1124\/dmd.106.013615.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"1757_CR37","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1177\/0091270011423662","volume":"52","author":"J Venitz","year":"2013","unstructured":"Venitz J, Zack J, Gillies H, et al. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2013;52(12):1784\u2013805. https:\/\/doi.org\/10.1177\/0091270011423662.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"1757_CR38","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40262-013-0063-8","volume":"52","author":"J Atsmon","year":"2013","unstructured":"Atsmon J, Dingemanse J, Shaikevich D, et al. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013;52(8):685\u201392. https:\/\/doi.org\/10.1007\/s40262-013-0063-8.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1757_CR39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1208\/s12248-011-9316-3","volume":"14","author":"S Bruderer","year":"2011","unstructured":"Bruderer S, A\u00e4nismaa P, Homery M-C, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J. 2011;14(1):68\u201378. https:\/\/doi.org\/10.1208\/s12248-011-9316-3.","journal-title":"AAPS J"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01757-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T21:06:39Z","timestamp":1732050399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01757-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1757"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01757-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3944627\/v1","asserted-by":"object"}]},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"10 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}